Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Most Popular

 
Title
Views
PDF
Cited
7.

CONCOMITANT CHEMORADIATION IN HEAD AND NECK CANCER: ROLE OF 5-FU ANALOGS.

Head and neck cancer forms the major chunk of cancer patients in developing country like India. About 2/3rd of the patients present in locally advanced stage in which the cure rates are low. Concomitant chemoradiation with platinum compounds is the standard treatment for such patients as it offers organ and function preservation with better quality of life. MACH-NC update (2009) shows that concomitant chemoradiation provides an absolute survival benefit of 6.5% at 5 years. Many chemotherapeutic agents including 5-FU, taxanes and biologically targeted therapy have been investigated in an effort to maximize the locoregional and survival in locally advanced head and neck cancer. Oral chemotherapeutic agent gives the ease of self medication on daily basis without the need for hospital admission and intravenous infusion. Theoretically daily administration of oral chemotherapy agent mimics the continous infusion of a parenteral agent. Since infusional 5-FU along with Radical RT has achieved a complete response rate of 68% for 5-FU arm versus 56% for placebo arm (p=0.04) with the overall median survival of 33 months for 5-FU versus 25 months for placebo arm, Capecitabine (analog of 5-FU) in low doses have been used in concomitant setting for locally advanced head and neck cancer. Overall response rate observed has been 33-89% with manageable toxicity and near total patient compliance. The maximally tolerated dose to be given daily during radiation therapy is 500 mg/m2 b.i.d. Lower dose doses of 250-350 mg/m2 have also been used in concomitant with lesser toxicity and greater...

Kailash Mittal, Anil Kumar Dhull, Rajeev Atri, Rakesh Dhankhar, Vivek Kaushal

Dr. Kailash Mittal, Assistant Professor, Department of Radiotherapy, UPRIMS&R, Saifai, Etawah (U.P.) INDIA

DOI:

35-46

3565

16

0

4.

PRIMARY ANAPLASTIC LARGE CELL LYMPHOMA OF BONE: MANAGING THE MISCELLANEOUS!

Anaplastic large cell lymphoma (ALCL) represents 2 to 3% of non-Hodgkin lymphoma (NHL). Anaplastic lymphoma kinase negative (ALK-) subtype accounts for 15-50% of all ALCL. Primary bone involvement in lymphoma is uncommon and constitutes less than 1% of all lymphomas and 4-5% of all extranodal NHL. Hence extra-nodal primary bone involvement in ALCL is even rarer. We report the 14th case of primary ALCL in a 38 year old Indian female. Other than the uncommon site, there is no reason not to keep NHL as differential diagnosis, as the condition responds too well to standard...

Sulbha Mittal, Yashpal Verma, Ashok K. Chauhan, Paramjeet Kaur, Anil Khurana, Nupur Bansal

Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA)

DOI:

25-29

3556

1502

0

8.

TARGETING IMMUNITY TO TREAT CANCERS- A BRIEF REVIEW

Cancer cells have a multitude of mechanisms to avoid and suppress immunity. Normal cells when exposed to chemical carcinogens, irradiation and certain viruses get transformed to cancer cells which can grow indefinitely. These cells have decreased requirements for growth factors; do not undergo apoptosis resulting in malignancy. The tumor cells have various antigens which are responsible for the generation of immune responses towards that particular tumor. There are two types of tumor antigens; tumors specific transplantation antigens (TSTAs) and tumor associated transplantation antigens (TATAs). The TSTAs are specific to tumor, result from mutations which alter the cellular proteins while TATAs may be proteins present in or during some stages of fetal development but not expressed or expressed at low levels in normal adult cells. Adoptive T-cell therapy involves the ex vivo cultivation of T cells with activity against a specific target cancer antigen to increase the frequency of these T cells to achieve therapeutic levels and then infuse them back into the patient. Oncolytic viruses selectively infect, replicate in, and kill tumor cells with no or limited impact on normal tissues which means that tumor cells have surface receptors to bind the virus. Monoclonal antibodies (mAbs) are immunoglobulins derived from a single clone of B cells, act by targeting an antigen which acts a ligand of receptor involved in signal transduction within the...

Nidhi Tejan, Varsha Gupta

Dr. Nidhi Tejan, Senior Resident, Department of Microbiology, SGPGI, Luknow, INDIA

DOI:

47-55

3384

1545

0

5.

UNUSUAL PRESENTATION OF NON-HODGKIN LYMPHOMA: VULVA GROWTH AND BREAST MASS IN THE SAME PATIENT

Primary involvement of vulva or breast by non-hodgkin lymphoma (NHL) is known to occur uncommonly. Only 24 cases of NHL vulva and around 250 cases of NHL breast alone have been reported, so far; but none with simultaneous involvement of the two sites together. We report the first case having both sites involved in a 35 year old Indian female.

Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal and Jagjeet Singh

Dr. Yashpal Verma, Medical Officer, Department of Radiotherapy, University of Health Sciences, Rohtak (INDIA). Contact no. +91-9416125026

DOI:

31-34

3379

1590

0

3.

PRIMARY RENAL LYMPHOMA: A RARE CASE REPORT

Primary renal Non-hodgkin lymphoma is rare. Most of the cases are unilateral though bilateral cases have been reported. Extrarenal involvement is to be excluded by imaging/ staging laprotomy for definitive diagnosis. We are presenting a case of 40-year-old Indian female who was attended with history of right flank pain for 3 years, found to have right renal mass on CT scan, underwent right radical nephrectomy and six courses of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) regimen subsequent to histo-pathological confirmation. Patient is asymptomatic on follow up of 18...

Mukesh Kumar, Paramjeet Kaur, Yashpal Verma, Anil Khurana, Nupur Bansal, Ashok K Chauhan

Department of Radiotherapy, Pt. BDS PGIMS Rohtak INDIA

DOI:

16-19

3378

1161

0

1.

IMPACT OF CHRONOMODULATED RADIOTHERAPY ON ACUTE SKIN TOXICITY IN CHEST WALL IRRADIATED BREAST CANCER PATIENTS – A SINGLE INSTITUTION ANALYSIS.

Abstract: We explored the possible association between the timing of delivery of radiation and the grade of skin reaction that develops in breast cancer patients receiving chest wall irradiation as adjuvant treatment after modified radical mastectomy. Invasive breast cancer patients, registered during the period of January 2013 – December 2014, who had undergone modified radical mastectomy followed by chest wall irradiation, were eligible for inclusion to the study. All the patients received chest wall external beam radiotherapy (EBRT) to a dose of 50 Gy in 25 fractions, one fraction a day, five days a week, delivered as tangential opposed pair, from a Cobalt 60 teletherapy source. Patients were stratified based on whether they received EBRT in the morning (between 8 am – 11 am) or in the evening between (5 pm – 8 pm). The clinicopathological characteristics of patients in both the arms were relatively well balanced. The incidence of higher grade of skin reaction (grade 3 or 4) was 22.5 % compared to 35.7 % in the morning and evening arms respectively, which was statistically significant (p = 0.039). The time to development of Grade 3 or 4 toxicity was 4.44 weeks compared to 4.11 weeks in the morning and evening arms respectively, suggesting that higher toxicity developed earlier in the patients receiving EBRT in the evening, though not statistically significant (p =...

Vipin George Kuriakose, Krishnanannair Jayakumar, Aravindh Anand, Anand Radha Krishnan, Divya Somasekharan

Dr. Vipin George Kuriakose, Department of Radiotherapy and Oncology, Government Medical College, Thiruvananthapuram INDIA

DOI:

1-7

3272

1623

0

1.

GESTATIONAL TROPHOBLASTIC DISEASE AND NEOPLASIA: DILEMMA AND UPDATES!

Gestational trophoblastic diseases include hydatidiform moles and gestational trophoblastic neoplasia i.e. invasive mole, choriocarcinoma, placental site trophoblastic tumor and epitheloid trophoblastic tumor. Incidence from India has been reported up to 2.4/ 1000 pregnancies, 2.5/ 1000 deliveries and 2.6/ 1000 live births. The standard protocols for management exist and are evolving fast. Though all gestational trophoblastic diseases are not malignant, still these need to be managed intensively, because of their potentially life threatening complications and common occurrence in fertility age group females. The better aspect is that; if timely and standard interventions are made; these are highly curable conditions, even with preservation of reproductive...

Dr. Yashpal Verma

Medical Officer, Civil Hospital, Sonepat (INDIA)

DOI:

1-9

3189

944

0

1.

PALLIATIVE CHEMORADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR MANAGEMENT OF LOCALLY ADVANCED HEAD & NECK CARCINOMA PATIENTS WITH POOR PERFORMANCE STATUS

Introduction: Palliative external beam radiotherapy (EBRT) and chemotherapy is commonly practiced for management of locally advanced head & neck carcinoma (LAHNC) patients with poor performance status. This study compares EBRT alone and EBRT along with low dose Gemcitabine. Method: Study was conducted in Department of Radiotherapy, PGIMS Rohtak, in 2008-09; on histopathologically proven, untreated 60 cases of LAHNC, having KPS 60-70. Patients were randomly assigned either control group (n=30), given EBRT alone as 20Gy/5Fr/5days or study group (n=30), given EBRT as 20Gy/ 5Fr/ 5days and Gemcitabine 200 mg/m2 i.v. 2 hour prior to radiotherapy on day 1. Mean age was 53 years (26-84 years). Male:female ratio was 5:1. Most common primary site was base of tongue followed by larynx. Major symptoms were pain, difficulty in swallowing and altered voice. Patients were staged as per AJCC 2002; 2/3rd were stage IVA and 1/3rd were IVB. Despite randomization, there was no significant difference between two groups in age, sex, primary site, stage, and performance status. The side effects were graded as per RTOG criteria. Results: Objective response, 3 months post-treatment, in the chemoradiotherapy and radiotherapy alone group respectively was: CR 7% vs 0%; PR 30% vs 33%; stable disease 56% vs 46% and progressive disease 7% vs 20%. Subjective response, similarly was better in study group through out; even significantly better in dysphagia at 3 months follow up. Acute skin reactions were: Grade I- 73% vs 47% at 2 weeks and 60% vs 40% at 1 month respectively. Acute mucosal reactions were: Grade I- 30% vs 17%, Grade II- 43% vs 17% respectively. No hematological and grade III/IV skin or mucosal reactions observed. Differences in reactions were not statistically significant. Conclusion: In management of LAHNC patients with poor performance status, addition of low dose Gemcitabine to palliative radiotherapy gives better disease control and symptomatic relief without unmanageable side...

Dinesh Ranga, Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal, Mukesh Bharti

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post-graduate institute of medical sciences, Rohtak (INDIA).

DOI:

01-09

3035

1140

0

1.

ASTROBLASTOMA: DOES IT REQUIRE DIFFERENT TREATMENT ?

Background- Astroblastoma is partially understood, poorly reported and rare in occurrence tumor with significant dilemma regarding cellular origin, diagnostic criteria, clinical behavior, and management protocol. Material and method– Thorough search of published English scientific literature was made with search word Astroblastoma through Google Search, PubMed, Research Gate and Cochrane Library till June 2018. The reports thus collected were examined for data regarding age, gender, location and laterality of disease, pathological grade, treatment received, and outcome of treatment. Results– Data of 161 patients was retrieved from 72 publications. Median age at presentation was 18 years. Females were affected much more frequently than males. Most common site of involvement was the frontal lobe. Laterality data was inconsistent and sparingly reported. Most common presenting complaint was headache followed by history of seizure. Surgery was performed in majority of patients-79.6% of the patients underwent a gross total resection, 45% (44 out of 98 reported) had a high-grade tumor. Sixty patients received adjuvant radiation with a median dose of 54 Gy (Range 20-72), mostly for high grade, residual or recurrent disease. Adjuvant chemotherapy was used in 25 patients. Median follow-up was 43 months (range 1-238). Median overall survival was 138 months. Patients with a higher-grade tumor had significantly worse overall survival. Conclusion- Astroblastoma is rare but known to have two distinct grades, with higher-grade tumors bearing significantly poor survival. Maximal safe surgery is the standard. Though there is lack of consensus, adjuvant radiotherapy with or without Temozolamide should be considered in view of high rates of local...

Dr. Yashpal Verma

Additional Senior Medical Officer, Department of Radiation Oncology, PGIMS, Rohtak (India)

DOI:

01-09

2916

706

0

1.

ASSESSMENT OF AWARENESS AND KNOWLEDGE ABOUT ORAL CANCER AMONG DENTAL PATIENTS IN BENGALURU.

Objective – Oral cancer is increasing at an alarming rate worldwide and is associated with heightened morbidity and mortality rates. Awareness regarding the signs and symptoms followed by early detection is the key for reducing the same. The present study was taken up to assess the awareness and knowledge regarding oral cancer among dental patients in Bengaluru (INDIA). Method – Study included 400 dental patients who visited the outpatient department of the institution. A questionnaire, adopted and modified from HOCKS scale (mHOCKS), was used to assess the awareness regarding risk factors, knowledge regarding symptoms and signs of oral cancer and general beliefs. Results –The total percentage scores obtained for awareness regarding risk factors, knowledge regarding symptoms and signs of oral cancer and general beliefs of oral cancer were 74.9%, 58.6% and 92.2% respectively. Irrespective of the age and gender, most of the subjects believed that it is easy to treat oral cancer, if detected early. Overall, the score of awareness and knowledge regarding oral cancer in the high-risk population of Bengaluru was, fairly good (75.23%).Conclusion – Although, the study group was having a sound knowledge regarding risk factors, unfortunately knowledge regarding the signs and symptoms of oral cancer was considerably lower. This is especially important for the clinicians, various governmental and non-governmental organization’s in providing specific goals, to concentrate on improving public knowledge about features of oral...

Anju Redhu, Suman B, Monica Venugopal, SindhuIyengar

Dr. Anju Redhu Senior Resident, Department of Oral Medicine and Radiology, Pt. B. D. Sharma PGIMS, Rohtak (INDIA) -124001

DOI:

1-8

2848

1191

0

Page 2 of 41234